Talk:Osimertinib: Difference between revisions

Content deleted Content added

Inline

Revision as of 00:43, 28 January 2018

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Osimertinib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

This article has not yet been rated on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Pharmacology Start‑class

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
???	This article has not yet received a rating on the project's importance scale.

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Medicine: Hematology-oncology / Genetics Start‑class Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.
	This article is supported by the Hematology-oncology task force.
	This article is supported by the Medical genetics task force.

EU approval Feb 2016

TAGRISSO™ (OSIMERTINIB) APPROVED IN EU AS FIRST-IN-CLASS TREATMENT FOR PATIENTS WITH EGFR T790M MUTATION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER refers to two Phase II studies (AURA extension and AURA2) - Rod57 (talk) 02:52, 4 February 2016 (UTC)[reply]

Nature Magazine as a source

Efforts to edit this article are being denied on the premise that Nature magazine is not a reliable souce. It is reliable and fits int he guildlines. — Preceding unsigned comment added by Lil bklyn (talk • contribs) 22:43, 26 January 2018 (UTC)[reply]

Please make sure you sign your posts on talk pages - you do that by typing exactly four tildas at the end -- when you click "save" the Wikipedia software will convert that into links to your user page and talk page, and date stamp it. Also as this evolves please thread your comments, as I have done here. See WP:THREAD.

Please do read WP:MEDRS, especially the WP:MEDDEF section. Not everything published in Nature (or any journal) is OK to use in WP for content about health. Thx Jytdog (talk) 03:56, 27 January 2018 (UTC)[reply]

I read them, and they have been noted. There is no reason to remove anything from Nature Magazing by the standards listed in those policies. The quotes in question are completely legitamate clinical trials and data listed in a reputable journal. I hope we have settled this now. Lil bklyn (talk) 00:28, 28 January 2018 (UTC)[reply]

Have asked for more input by the folks at WP:MED; we do not use primary sources like this unless there is very good reason and you have not given any. Jytdog (talk) 00:33, 28 January 2018 (UTC)[reply]

The notation in question is factually and medically true: "In people treated with osimertinib, resistance develops usually within 10 months etc" Please do not remove it again unless you have contradicting data. It is an essential characteristic of treatment with this drug. In addition, there is support with these links:

https://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0290-1 http://www.onclive.com/peer-exchange-archive/nsclc9-advances/osimertinib-for-the-t790m-resistance-mutation http://www.cancertherapyadvisor.com/iaslc-2017/lung-cancer-nsclc-repeat-t790m-tki-resistant-recommendation/article/700530/ http://www.tandfonline.com/doi/abs/10.1586/14737140.2016.1162103 http://www.jto.org/article/S1556-0864%2817%2931435-1/abstract